{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:01:25Z","timestamp":1790917285937,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clim.2020.108652","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T06:00:06Z","timestamp":1608098406000},"page":"108652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"special_numbering":"C","title":["Influenza infection, SARS, MERS and COVID-19: Cytokine storm \u2013 The common denominator and the lessons to be learned"],"prefix":"10.1016","volume":"223","author":[{"given":"Varvara A.","family":"Ryabkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid P.","family":"Churilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108652_bb0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3906\/sag-2004-126","article-title":"Emerging and reemerging respiratory viral infections up to covid-19","volume":"50","author":"\u00c7elik","year":"2020","journal-title":"Turkish J. Med. Sci."},{"key":"10.1016\/j.clim.2020.108652_bb0010","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR project","volume":"9","author":"Paget","year":"2019","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.clim.2020.108652_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2018.01.002","article-title":"The role of adjuvant immunomodulatory agents for treatment of severe influenza","volume":"150","author":"Hui","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.clim.2020.108652_bb0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-017-0640-2","article-title":"Cytokine storms in infectious diseases","volume":"39","author":"Teijaro","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.clim.2020.108652_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fimmu.2020.01131","article-title":"Lessons learned to date on COVID-19 Hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation","volume":"11","author":"Cardone","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0035","first-page":"161","article-title":"Cytokines in the systemic inflammatory response syndrome: a review","volume":"2","author":"Jaffer","year":"2010","journal-title":"HSR Proc. Intensive Care Cardiovasc. Anesth."},{"key":"10.1016\/j.clim.2020.108652_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1741-7015-11-185","article-title":"The Hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome","volume":"11","author":"Ros\u00e1rio","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.clim.2020.108652_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","article-title":"Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating Hemophagocytic syndromes","volume":"59","author":"Canna","year":"2012","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.clim.2020.108652_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.clim.2020.108652_bb0060","doi-asserted-by":"crossref","first-page":"e1102","DOI":"10.1038\/cddis.2014.70","article-title":"Extracellular ATP drives systemic inflammation, tissue damage and mortality","volume":"5","author":"Cauwels","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0065","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"101","author":"Bone","year":"1992","journal-title":"Chest."},{"key":"10.1016\/j.clim.2020.108652_bb0070","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-125-8-199610150-00009","article-title":"Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)","volume":"125","author":"Bone","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clim.2020.108652_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine storms: understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2020.108652_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","article-title":"Influenza virus-related critical illness: pathophysiology and epidemiology","volume":"23","author":"Kalil","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2020.108652_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/cc12512","article-title":"Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO","volume":"17","author":"Zangrillo","year":"2013","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2020.108652_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fmicb.2014.00653","article-title":"Influenza virus and endothelial cells: a species specific relationship","volume":"5","author":"Short","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.clim.2020.108652_bb0100","series-title":"Cytokine Storm Syndr","first-page":"277","article-title":"Cytokine storm syndrome associated with Hemorrhagic fever and other viruses","author":"Sen","year":"2019"},{"key":"10.1016\/j.clim.2020.108652_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5694\/mja2.50674","article-title":"COVID\u201019 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre\u2010COVID\u201019 ARDS","volume":"213","author":"Gibson","year":"2020","journal-title":"Med. J. Aust. preprint"},{"key":"10.1016\/j.clim.2020.108652_bb0110","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/jimmunol.1402513","article-title":"The acute respiratory distress syndrome: from mechanism to translation","volume":"194","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0115","article-title":"The pathogenesis and treatment of the \u201ccytokine storm\u201d in COVID-19","author":"Ye","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1055\/s-0032-1325158","article-title":"Acute interstitial pneumonia (AIP): relationship to hamman-rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS)","volume":"33","author":"Mukhopadhyay","year":"2012","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2020.108652_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.forsciint.2006.12.002","article-title":"An immunohistochemical study in a fatal case of acute interstitial pneumonitis (Hamman\u2013rich syndrome) in a 15-year-old boy presenting as sudden death","volume":"173","author":"Turillazzi","year":"2007","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.clim.2020.108652_bb0130","first-page":"4","article-title":"Diagnosis of the diseases of tespiratory system and its pathophysiological basis. III. Cor pulmonale \u2013 pulmonary heart disease., Rus","volume":"5","author":"Stroev","year":"2020","journal-title":"Biomed. Res."},{"key":"10.1016\/j.clim.2020.108652_bb0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0974-2700.96484","article-title":"Correlation of C-reactive protein to severity of symptoms in acute influenza a infection","volume":"5","author":"Haran","year":"2012","journal-title":"J. Emerg. Trauma Shock."},{"key":"10.1016\/j.clim.2020.108652_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2016.01.009","article-title":"A new perspective on C-reactive protein in H7N9 infections","volume":"44","author":"Wu","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00011-018-1188-x","article-title":"C-reactive protein as a biomarker of severe H1N1 influenza","volume":"68","author":"Vasileva","year":"2019","journal-title":"Inflammation Research"},{"key":"10.1016\/j.clim.2020.108652_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.02.018","article-title":"Elevation of serum ferritin levels for predicting a poor outcome in hospitalized patients with influenza infection","author":"Lalueza","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.clim.2020.108652_bb0160","article-title":"Serum ferritin as an independent risk factor for severity in COVID-19 patients","volume":"0","author":"Lin","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01423","article-title":"Cytokine profiles of severe influenza virus-related complications in children","volume":"8","author":"Fiore-Gartland","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00281-017-0636-y","article-title":"New fronts emerge in the influenza cytokine storm","volume":"39","author":"Guo","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.clim.2020.108652_bb0175","first-page":"5593","article-title":"Clinical aspects and cytokine response in adults with seasonal influenza infection","volume":"7","author":"Bian","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0180","first-page":"2019","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"2019","author":"Jose","year":"2019","journal-title":"Lancet Respir."},{"key":"10.1016\/j.clim.2020.108652_bb0185","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/cmi.2016.1","article-title":"Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia","volume":"13","author":"Yang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0190","article-title":"Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.clim.2020.108652_bb0195","first-page":"1","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2020.108652_bb0200","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/23744235.2019.1598572","article-title":"Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome","volume":"51","author":"Lalueza","year":"2019","journal-title":"Infect. Dis. (Auckl.)"},{"key":"10.1016\/j.clim.2020.108652_bb0205","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2020.108652_bb0210","article-title":"Unique immunological profile in patients with COVID-19","author":"Varchetta","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0215","article-title":"Storm of soluble immune checkpoints associated with disease severity of COVID-19","volume":"5","author":"Kong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2020.108652_bb0220","article-title":"Elevated plasma sTIM-3 levels in patients with severe COVID-19","volume":"0","author":"Ueland","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fimmu.2016.00229","article-title":"TIM-3 regulates distinct functions in macrophages","volume":"7","author":"Oca\u00f1a-Guzman","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0230","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.4049\/jimmunol.1102483","article-title":"Enhanced Tim3 activity improves survival after influenza infection","volume":"189","author":"Cho","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0235","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10753-014-0096-7","article-title":"Regulatory T cells contribute to the recovery of acute lung injury by upregulating Tim-3","volume":"38","author":"Song","year":"2015","journal-title":"Inflammation."},{"key":"10.1016\/j.clim.2020.108652_bb0240","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1172\/JCI62860","article-title":"Viral acute lower respiratory infections impair CD8 + T cells through PD-1","volume":"122","author":"Erickson","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2020.108652_bb0245","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/989673","article-title":"PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response","volume":"2013","author":"Valero-Pacheco","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0250","doi-asserted-by":"crossref","first-page":"12916","DOI":"10.1128\/JVI.02423-13","article-title":"Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection","volume":"87","author":"McNally","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2020.108652_bb0255","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/JVI.02851-13","article-title":"Highly pathological influenza a virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells","volume":"88","author":"Rutigliano","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2020.108652_bb0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jix571","article-title":"Severe influenza is characterized by prolonged immune activation: results from the SHIVERS cohort study - PubMed","volume":"217","author":"Wong","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0270","article-title":"Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19)","author":"Diao","year":"2020","journal-title":"MedRxiv."},{"key":"10.1016\/j.clim.2020.108652_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102562","article-title":"Cytokine storm syndrome in severe COVID-19","volume":"19","author":"Ruscitti","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0280","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.autrev.2020.102569","article-title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review","volume":"19","author":"Alijotas-Reig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4049\/jimmunol.2000413","article-title":"COVID-19 as an acute inflammatory disease","volume":"205","author":"Manjili","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0290","first-page":"e82","article-title":"CD4+T, CD8+T counts and severe COVID-19: a meta-analysis","volume":"81","author":"Zhang","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0295","unstructured":"B. Burt, Cyclosporine For The Treatment Of COVID-19(+) NLM identifier: NCT04492891 - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04492891 (accessed November 29, 2020)."},{"key":"10.1016\/j.clim.2020.108652_bb0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41420-020-0283-2","article-title":"Off-label therapy targeting pathogenic inflammation in COVID-19","volume":"6","author":"Romani","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0305","first-page":"e89","article-title":"Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19","volume":"81","author":"Goursaud","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb5000","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00361","article-title":"Modulating the innate immune response to influenza A virus: Potential therapeutic use of anti-inflammatory drugs","volume":"6","author":"Ramos","year":"2015","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.clim.2020.108652_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/IJN.S221667","article-title":"Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus","volume":"15","author":"Huo","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.clim.2020.108652_bb0320","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fimmu.2019.01393","article-title":"Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0325","first-page":"O0815","article-title":"O0815 treatment of severe influenza a infection with celecoxib\u00a0: a double-blind, randomised, controlled trial, in: proc. 29th ECCMID 13-16 April 2019","author":"Hung","year":"2019","journal-title":"Amsterdam"},{"key":"10.1016\/j.clim.2020.108652_bb0330","author":"US National Institute of Health"},{"key":"10.1016\/j.clim.2020.108652_bb0335","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"MedRxiv.Org the Prepr. Serv. Heal. Sci."},{"key":"10.1016\/j.clim.2020.108652_bb0340","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S2213-8587(20)30216-3","article-title":"Association between high serum total cortisol concentrations and mortality from COVID-19","volume":"8","author":"Tan","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.clim.2020.108652_bb0345","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.2005.02325.x","article-title":"Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)","volume":"63","author":"Leow","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.clim.2020.108652_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2020.108652_bb0355","first-page":"1","article-title":"Practical aspects of targeting IL-6 in COVID-19 disease: Posted april 21, 2020","volume":"87","author":"Calabrese","year":"2020","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0360","article-title":"Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes","volume":"0","author":"Price","year":"2020","journal-title":"Chest."},{"key":"10.1016\/j.clim.2020.108652_bb0365","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0370","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating influenza infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0375","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201ccytokine storm\u201d relevant to COVID-19?","author":"Sinha","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0380","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.clim.2020.108652_bb0385","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clim.2020.108652_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155190","article-title":"Cytokine prediction of mortality in COVID19 patients","volume":"134","author":"Mandel","year":"2020","journal-title":"Cytokine."},{"key":"10.1016\/j.clim.2020.108652_bb0395","first-page":"452","article-title":"Interleukin-6 as prognosticator in patients with COVID-19","volume":"81","author":"Grifoni","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0400","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0405","first-page":"ciaa641","article-title":"Prognostic value of C-reactive protein in patients with COVID-19","author":"Luo","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0410","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1073\/pnas.1321748111","article-title":"Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2020.108652_bb0415","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-10-288","article-title":"C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection","volume":"10","author":"Zimmerman","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0420","first-page":"DC56","article-title":"Cut-off levels of CRP to predict outcomes in patients with influenza infection","volume":"12","author":"Karasahin","year":"2018","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.clim.2020.108652_bb0425","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-12-83","article-title":"Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study","volume":"12","author":"Komiya","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.clim.2020.108652_bb0430","article-title":"Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19","volume":"22","author":"Keller","year":"2020","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104444","article-title":"Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care","volume":"129","author":"Quartuccio","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.clim.2020.108652_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102570","article-title":"Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: an immunological point of view","volume":"19","author":"Kronbichler","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108652_bb0445","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.jaut.2020.102511","article-title":"Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients","author":"Canziani","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2020.108652_bb0450","article-title":"Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab","volume":"102512","author":"Morrison","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2020.108652_bb0455","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijid.2020.04.086","article-title":"Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis","volume":"96","author":"Zhao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0460","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.200645","article-title":"Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis","volume":"192","author":"Ye","year":"2020","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.clim.2020.108652_bb0465","first-page":"1","article-title":"Corticosteroid administration for viral pneumonia: COVID-19 and beyond","author":"Yang","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.clim.2020.108652_bb0470","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(10)61345-1","article-title":"Cytotoxic therapy for severe swine flu A\/H1N1","volume":"376","author":"Henter","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2020.108652_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19160","article-title":"Blinded randomised controlled trial of low-dose adjuvant steroids in adults admitted to hospital with pandemic influenza (ASAP): a trial \u2018in hibernation\u2019, ready for rapid activation","volume":"19","author":"Lim","year":"2015","journal-title":"Health Technol. Assess. (Rockv)."},{"key":"10.1016\/j.clim.2020.108652_bb0480","first-page":"cciaa829","article-title":"High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19","author":"Li","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0485","first-page":"147","article-title":"Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19","volume":"81","author":"Fang","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0490","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID\u201319: A retrospective cohort study","author":"Kewan","year":"2020","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.clim.2020.108652_bb0495","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3109\/s10165-012-0780-0","article-title":"Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab","volume":"23","author":"Kawada","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.clim.2020.108652_bb0500","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/mi.2012.2","article-title":"Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung","volume":"5","author":"Dienz","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.clim.2020.108652_bb0505","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0510","article-title":"Time to reassess Tocilizumab\u2019s role in COVID-19 pneumonia","author":"Parr","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0515","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","author":"Hermine","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0520","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","author":"Salvarani","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0525","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2020.108652_bb0530","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2020.108652_bb0535","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study","volume":"0","author":"Balkhair","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0540","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1189\/jlb.4MR0616-288R","article-title":"Hero turned villain: NLRP3 inflammasome-induced inflammation during influenza a virus infection","volume":"101","author":"Ong","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2020.108652_bb0545","doi-asserted-by":"crossref","first-page":"64443","DOI":"10.1371\/journal.pone.0064443","article-title":"Complement C5 activation during influenza a infection in mice contributes to neutrophil recruitment and lung injury","volume":"8","author":"Garcia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2020.108652_bb0550","article-title":"Therapeutic plasma exchange in adults with severe COVID-19 infection","volume":"0","author":"Khamis","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0555","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3904\/kjim.2014.29.1.132","article-title":"Severe influenza treatment guideline","volume":"29","author":"Choi","year":"2014","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0560","first-page":"3","article-title":"Observational study of people infected with SARS-Cov-2, treated with amantadine","volume":"1","author":"Aranda-Abreu","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.clim.2020.108652_bb0565","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jpm10040217","article-title":"Anti-inflammatory effects of amantadine and memantine: possible therapeutics for the treatment of Covid-19?","volume":"10","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2020","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.clim.2020.108652_bb0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine","volume":"530","author":"Singh Tomar","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2020.108652_bb0575","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","article-title":"The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus","volume":"12","author":"Tanner","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.clim.2020.108652_bb0580","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(20)32078-X","article-title":"Antiviral monotherapy for hospitalised patients with COVID-19 is not enough","volume":"396","author":"Cao","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2020.108652_bb0585","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108652_bb0590","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2020.108652_bb0595","series-title":"Predictors of Mortality in Middle East Respiratory Syndrome ( MERS )","first-page":"1","author":"First","year":"2017"},{"key":"10.1016\/j.clim.2020.108652_bb0600","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1128\/IAI.72.8.4410-4415.2004","article-title":"Analysis of serum cytokines in patients with severe acute respiratory syndrome","volume":"72","author":"Zhang","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.clim.2020.108652_bb0605","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1726-4901(09)70231-X","article-title":"Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS Center in Taiwan","volume":"68","author":"Liu","year":"2005","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.clim.2020.108652_bb0610","first-page":"468","article-title":"Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients","volume":"73","author":"Ko","year":"2016","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108652_bb0615","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3201\/eid1003.030571","article-title":"Patient data, early SARS epidemic, Taiwan","volume":"10","author":"Hsueh","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108652_bb0620","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1128\/JVI.02340-09","article-title":"Inhibition of human natural killer cell activity by influenza Virions and hemagglutinin","volume":"84","author":"Mao","year":"2010","journal-title":"J. Virol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620308123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620308123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:03:23Z","timestamp":1761494603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620308123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":124,"alternative-id":["S1521661620308123"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108652","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influenza infection, SARS, MERS and COVID-19: Cytokine storm \u2013 The common denominator and the lessons to be learned","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108652"}}